{"analyses":[{"ciLowerLimit":"-8.44","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"6.64","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","pValue":"0.7857","paramType":"Difference in response rate","paramValue":"-0.90","statisticalMethod":"Cochran-Mantel-Haenszel"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"77.49","upperLimit":"88.05","value":"83.3"},{"groupId":"OG001","lowerLimit":"76.42","upperLimit":"87.32","value":"82.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"209"},{"groupId":"OG001","value":"204"}],"units":"Participants"}],"description":"Objective response was defined as having CR or PR as assessed according to the modified response criteria for iNHL (Modified Cheson et al, 2007). CR: Complete disappearance of all detectable clinical evidence of disease and disease-related symptoms if present prior to therapy, liver and spleen have returned to normal size (if enlarged at baseline), If the bone marrow was involved by lymphoma prior to treatment, the infiltrate must have cleared on repeat bone marrow biopsy. PR: at least 50% regression of measurable disease compared to tumors measured by a baseline scan and no new sites; no increase in the size of the other nodes, liver, or spleen; with the exception of splenic and hepatic nodules, involvement of other organs is usually assessable and no measurable disease should be present.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received Bendamustine 120 mg/m\\^2 IV infusion on Days 1 and 2 of each 28-day cycle for up to six cycles.","id":"OG000","title":"Bendamustine Alone"},{"description":"Induction phase: Participants received Bendamustine 90 mg/m\\^2 IV on Days 2 and 3 of Cycle 1 and on Days 1 and 2 of Cycles 2-6 (28-day cycles) for the first 10 participants and on Days 1 and 2 of each 28-day cycle for Cycles 1-6 for remaining participants. Participants also received obinutuzumab 1000 mg IV infusion on Days 1, 8, and 15 of Cycle 1; Day 1 of Cycles 2-6. Maintenance phase: Participants with CR, PR or SD then received obinutuzumab 1000 mg IV infusion every 2 months until disease progression or for up to 2 years (whichever occurred first).","id":"OG001","title":"Obinutuzumab + Bendamustine"}],"paramType":"NUMBER","populationDescription":"ITT population. Here, number of participants analyzed signified those participants who had at least one post-baseline assessment.","reportingStatus":"POSTED","timeFrame":"Baseline until PD or death, whichever occurred first (up to approximately 8.5 years)","title":"Percentage of Participants With Objective Response as Assessed by Investigator","type":"SECONDARY","unitOfMeasure":"percentage of participants"}